Prometic, Shenzhen Hepalink Pharmaceutical deal

The companies partnered to research and develop ProMetic's protein technologies. ProMetic will receive $2 million up front, and is eligible to receive up to $9 million in licensing fees and milestone payments. Shenzhen Hepalink said the deal is designed to provide it with bioprocesses as part of its product expansion and diversification activities. Shenzhen Hepalink also said the deal is expected to lead to a subsequent long-term manufacturing agreement between the companies. ...